149 related articles for article (PubMed ID: 37885116)
1. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to
Batra V; Gikandi A; Pawel B; Martinez D; Granger MM; Marachelian A; Park JR; Maris JM; Vo KT; Matthay KK; DuBois SG
Pediatr Blood Cancer; 2024 Jan; 71(1):e30743. PubMed ID: 37885116
[TBL] [Abstract][Full Text] [Related]
2. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
Temple W; Mendelsohn L; Kim GE; Nekritz E; Gustafson WC; Lin L; Giacomini K; Naranjo A; Van Ryn C; Yanik GA; Kreissman SG; Hogarty M; Matthay KK; DuBois SG
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):474-481. PubMed ID: 26338179
[TBL] [Abstract][Full Text] [Related]
3. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.
Zhao Y; Zhong X; Ou X; Cai H; Wu X; Huang R
Front Med; 2017 Mar; 11(1):120-128. PubMed ID: 28213878
[TBL] [Abstract][Full Text] [Related]
4. The Plasma Membrane Monoamine Transporter is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter.
Vieira LS; Zhang Y; López Quiñones AJ; Hu T; Singh DK; Stevens J; Prasad B; Park JR; Wang J
J Pharmacol Exp Ther; 2023 Dec; 387(3):239-248. PubMed ID: 37541765
[TBL] [Abstract][Full Text] [Related]
5. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
[TBL] [Abstract][Full Text] [Related]
6. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
7. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
[TBL] [Abstract][Full Text] [Related]
8. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
9. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
[TBL] [Abstract][Full Text] [Related]
10.
Turnock S; Turton DR; Martins CD; Chesler L; Wilson TC; Gouverneur V; Smith G; Kramer-Marek G
Sci Rep; 2020 Dec; 10(1):20918. PubMed ID: 33262374
[TBL] [Abstract][Full Text] [Related]
11. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.
Alexander N; Marrano P; Thorner P; Naranjo A; Van Ryn C; Martinez D; Batra V; Zhang L; Irwin MS; Baruchel S
J Pediatr Hematol Oncol; 2019 Apr; 41(3):222-227. PubMed ID: 30334904
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
[TBL] [Abstract][Full Text] [Related]
14.
Kitamura Y; Baba S; Isoda T; Maruoka Y; Sasaki M; Kamitani T; Koga Y; Kawakubo N; Matsuura T; Ishigami K
Ann Nucl Med; 2021 May; 35(5):549-556. PubMed ID: 33586098
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
Messina JA; Cheng SC; Franc BL; Charron M; Shulkin B; To B; Maris JM; Yanik G; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2006 Dec; 47(7):865-74. PubMed ID: 16444675
[TBL] [Abstract][Full Text] [Related]
16. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
DuBois SG; Mody R; Naranjo A; Van Ryn C; Russ D; Oldridge D; Kreissman S; Baker DL; Parisi M; Shulkin BL; Bai H; Diskin SJ; Batra V; Maris JM; Park JR; Matthay KK; Yanik G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383813
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
18. MIBG in neuroblastoma diagnosis and treatment.
Olecki E; Grant CN
Semin Pediatr Surg; 2019 Dec; 28(6):150859. PubMed ID: 31931960
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
DuBois SG; Matthay KK
Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
[TBL] [Abstract][Full Text] [Related]
20. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
